Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4617514 | 1.00 | HTR4 (0.41) | HTR4CHRM2CHRM1CHRM3CACNA1G | |
| SCHEMBL4618827 | 0.90 | HTR4 (0.39) | HTR4CHRM2CHRM1CHRM3CACNA1G | |
| SCHEMBL5106216 | 0.89 | CHRM3 (0.39) | HTR4CHRM2CHRM1CHRM3CACNA1G | |
| SCHEMBL4149426 | 0.89 | CHRM3 (0.39) | HTR4CHRM2CHRM1CHRM3CACNA1G | |
| SCHEMBL5105568 | 0.85 | CHRM3 (0.46) | CHRM2CHRM1CHRM3S1PR1S1PR5 | |
| SCHEMBL5105573 | 0.85 | CHRM3 (0.46) | CHRM2CHRM1CHRM3S1PR1S1PR5 | |
| SCHEMBL5099505 | 0.81 | CHRM3 (0.45) | CHRM2CHRM1CHRM3S1PR1S1PR5 | |
| SCHEMBL4136290 | 0.81 | CHRM3 (0.45) | CHRM2CHRM1CHRM3S1PR1S1PR5 | |
| SCHEMBL4140791 | 0.81 | SSTR4 (0.44) | CHRM2CHRM1CHRM3CYP2D6 | |
| SCHEMBL4140788 | 0.81 | SSTR4 (0.44) | CHRM2CHRM1CHRM3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021487-A1 | Azabicyclo derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021487-A1 | Azabicyclo derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | HTR4 397/4885CHRM2 3/4885CHRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.